DMR-001 / Galecto - LARVOL DELTA

An IND submission for DMR-001, with anticipated first-in-human administration via subcutaneous administration, is expected to occur in mid-2026 (GlobeNewswire)

First-in-human • IND • Essential Thrombocythemia • Myelofibrosis

Galecto Announces Acquisition of Damora Therapeutics (GlobeNewswire) - "The acquisition gives the combined company a pipeline covering a broad spectrum of hematological cancers and leverages the deep expertise of both teams, and positions Galecto to advance Damora’s complementary assets for people living with blood cancers....The private placement resulted in gross proceeds to Galecto of approximately $284.9 million and is expected to fund operations into 2029, enabling advancement of Damora’s lead program, DMR-001, through key Phase 1 proof-of-concept data expected in 2027, as well as pipeline programs, DMR-002 and DMR-003, into Phase 1 studies."

M&A • P1 data • Essential Thrombocythemia • Myelofibrosis